STIs/STDs

FDA approves first two-drug regimen for HIV

On Nov. 21, the U.S. Food and Drug Administration (FDA) approved Juluca, the first treatment regimen containing two drugs to treat certain adults with...

HIV patients at greater risk for heart, kidney disease

Patients with HIV who are at high risk for a heart attack or stroke are also at substantially greater risk for chronic kidney disease...

Guideline for management of chronic pain in persons with HIV

The Infectious Diseases Society of American has released a guideline for managing chronic pain in persons living with HIV. The guideline includes management of...

WHO issues new HIV treatment recommendations

According to a new guideline from the World Health Organization (WHO), anyone infected with HIV should begin antiretroviral treatment as soon after diagnosis as...

New intravaginal ring

Researchers have developed a new intravaginal ring for the sustained 90-day co-delivery of tenofovir and levonorgestrel, an anti-human immunodeficiency virus (HIV) drug and a...

WHO releases guidelines for antiretroviral drugs in HIV

The World Health Organization (WHO) has released “Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection.” Access the guidelines.

Caring for older lesbian, gay, bisexual, and transgender adults

Current discussions on the unique health issues of lesbian, gay, bisexual, and transgender (LGBT) populations have prompted the healthcare professions to reexamine their mission...

Moving the Sharps Safety Agenda Forward: Consensus Statement and Call to Action

Note: This Consensus Statement and Call to Action was drafted by members of the steering committee* for the conference "Tenth Anniversary of the Needlestick...

Choosing wisely: Resources for selecting sharps safety devices

An essential part of a sharps safety program is selecting appropriate devices, such as safety needles. While no one device, feature, or mechanism of...

HAART and its effects on the heart

Many patients with HIV/AIDS are doing well on highly active antiretroviral therapy (HAART). Yet HAART can increase cardiovascular risks by reducing high-density lipoprotein levels, raising triglyceride levels, and causing insulin resistance.